Regentis Biomaterials Ltd.

Healthcare · Other · Israel

Last price 1.37 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 9.62M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.